Study of COVID-19 Risk Factors, Immune Response, and Long-Term Effects in Hospitalized Norwegian Children Aged 0 to 18 Years

What this Trial Is About

This research investigates COVID-19 infection in children aged 0 to 18 years who are hospitalized in Norway. It aims to study three key areas factors that increase the risk of severe illness, the bodys immune response during infection, and the long-term effects, including persistent fatigue after infection. The study is designed as a nationwide, prospective cohort to better understand how the disease affects children. Children admitted with suspected COVID-19 are enrolled and grouped based on whether they test positive or negative for the virus. Those confirmed positive form the case group, while those negative serve as controls. Both groups are followed for six months to assess outcomes and immune responses. The study includes three focused work areas risk factors for severe illness, immunological mechanisms during acute infection, and the prevalence and risks of long-lasting complications. Participants will undergo monitoring and assessments over six months to track their health outcomes, immune reactions, and any chronic symptoms that may develop. Researchers will collect clinical data and evaluate the natural history of the infection, including genetic and inflammatory factors. The primary outcomes measured are risk factors for severe infection, immunological responses, and long-term health consequences related to COVID-19 in hospitalized children.

COVID-19 in Hospitalised Norwegian Children - Risk Factors, Outcomes and Immunology